» Articles » PMID: 31896555

Vaccinia Virus Vectors Targeting Peptides for MHC Class II Presentation to CD4 T Cells

Overview
Journal Immunohorizons
Date 2020 Jan 4
PMID 31896555
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

CD4 helper T cells play important roles in providing help to B cells, macrophages, and cytotoxic CD8 T cells, but also exhibit direct effector functions against a variety of different pathogens. In contrast to CD8 T cells, CD4 T cells typically exhibit broader specificities and undergo less clonal expansion during many types of viral infections, which often makes the identification of virus-specific CD4 T cells technically challenging. In this study, we have generated recombinant vaccinia virus (VacV) vectors that target I-A-restricted peptides for MHC class II (MHC-II) presentation to activate CD4 T cells in mice. Conjugating the lymphocytic choriomeningitis virus immunodominant epitope GP to either LAMP1 to facilitate lysosomal targeting or to the MHC-II invariant chain (Ii) significantly increased the activation of Ag-specific CD4 T cells in vivo. Immunization with VacV-Ii-GP activated endogenous Ag-specific CD4 T cells that formed memory and rapidly re-expanded following heterologous challenge. Notably, immunization of mice with VacV expressing an MHC-II-restricted peptide from species (PEPCK) conjugated to either LAMP1 or Ii also generated Ag-specific memory CD4 T cells that underwent robust secondary expansion following a visceral leishmaniasis infection, suggesting this approach could be used to generate Ag-specific memory CD4 T cells against a variety of different pathogens. Overall, our data show that VacV vectors targeting peptides for MHC-II presentation is an effective strategy to activate Ag-specific CD4 T cells in vivo and could be used to study Ag-specific effector and memory CD4 T cell responses against a variety of viral, bacterial, or parasitic infections.

Citing Articles

The unique immune evasion mechanisms of the mpox virus and their implication for developing new vaccines and immunotherapies.

Fang D, Liu Y, Dou D, Su B Virol Sin. 2024; 39(5):709-718.

PMID: 39181538 PMC: 11738799. DOI: 10.1016/j.virs.2024.08.008.


T helper 1 effector memory CD4 T cells protect the skin from poxvirus infection.

Harbour J, Abdelbary M, Schell J, Fancher S, McLean J, Nappi T Cell Rep. 2023; 42(5):112407.

PMID: 37083328 PMC: 10281076. DOI: 10.1016/j.celrep.2023.112407.


Design and Immunological Validation of Papillomavirus Type 3 Based Vaccine Candidates in Outbred Mice: Basis for Future Testing of a Therapeutic Papillomavirus Vaccine in NHPs.

Neckermann P, Boilesen D, Willert T, Pertl C, Schrodel S, Thirion C Front Immunol. 2021; 12:761214.

PMID: 34777375 PMC: 8581358. DOI: 10.3389/fimmu.2021.761214.


Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein.

Harbour J, Lyski Z, Schell J, Thomas A, Messer W, Slifka M J Immunol. 2021; 206(11):2596-2604.

PMID: 33972374 PMC: 8165000. DOI: 10.4049/jimmunol.2100054.

References
1.
Osborn J, Hobbs S, Mooster J, Khan T, Kilgore A, Harbour J . Central memory CD8+ T cells become CD69+ tissue-residents during viral skin infection independent of CD62L-mediated lymph node surveillance. PLoS Pathog. 2019; 15(3):e1007633. PMC: 6420010. DOI: 10.1371/journal.ppat.1007633. View

2.
Soghoian D, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T . HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci Transl Med. 2012; 4(123):123ra25. PMC: 3918726. DOI: 10.1126/scitranslmed.3003165. View

3.
Rodriguez F, Harkins S, Redwine J, de Pereda J, Whitton J . CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol. 2001; 75(21):10421-30. PMC: 114616. DOI: 10.1128/JVI.75.21.10421-10430.2001. View

4.
Miller M, Ganesan A, Luckashenak N, Mendonca M, Eisenlohr L . Endogenous antigen processing drives the primary CD4+ T cell response to influenza. Nat Med. 2015; 21(10):1216-22. PMC: 4629989. DOI: 10.1038/nm.3958. View

5.
Roche P, Furuta K . The ins and outs of MHC class II-mediated antigen processing and presentation. Nat Rev Immunol. 2015; 15(4):203-16. PMC: 6314495. DOI: 10.1038/nri3818. View